Spotlight on rotigotine in Parkinson's disease

Drugs and Aging

Volumn 25, Issue 2, 2008, Pages 175-177

  Baldwin, Claudine M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Parkinson's disease; Rotigotine, therapeutic use

Indexed keywords

PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

DAILY LIFE ACTIVITY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HALLUCINATION; HUMAN; IN VITRO STUDY; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VOMITING;

EID: 38949188722     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825020-00009     Document Type: Review

References (15)

1. Schwarz Pharma. US prescribing information [online]. Available from URL: http://www.neupro.com [Accessed 2007 Aug 2]
2. Schwarz Pharma. EU prescribing information [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Aug 2]
3. Scheller DKA. Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist for the treatment of Parkinson's disease [abstract no. P94]. Mov Disord 2006; 21 Suppl. 13: S80
4. European Medicines Agency. European Public Assessment Report (EPAR): Neupro [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Aug 2]
5. Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994 Mar; 9 (2): 147-54
6. Rose S, Scheller DK, Breidenbach A, et al. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol 2007 Mar; 18 (2): 155-60
7. Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation [abstract no. 250]. Ann Neurol 2004; 56 Suppl. 8: S54 plus poster presented at the 129th Annual Meeting of the American Neurological Association; 2004 Oct 3-6; Toronto (ON)
8. Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol 2007 Feb; 203 (2): 415-22
9. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003 Dec; 60 (12): 1721-8
10. Bianchine J, Poole K. Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early parkinson's disease. Neurology 2002; 58 Suppl. 3: A162-3
11. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007 Dec; 22 (16): 2398-404
12. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 Jan 23; 68 (4): 272-6
13. Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007 May; 64 (5): 676-82
14. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007 Apr 17; 68 (16): 1262-7
15. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 Jun; 6 (6): 513-20